Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Management of pediatric CP-CML in the TKI era & additional considerations in this patient population

Nirmalya Roy Moulik • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Imatinib

Nirmalya Roy Moulik, MD, PhD, MRCPCH, Tata Memorial Centre, Mumbai, India, comments on the treatment of children with chronic myeloid leukemia in the chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era, highlighting the long-term toxicities associated with TKI therapy in this patient population and the importance of monitoring these patients for adverse events to intervene where necessary. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nirmalya Roy Moulik

1:06
The challenges of managing children with CML in a resource-constrained country
Nirmalya Roy Moulik • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals